Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group trial

Registry ID

EUCTR2008-002325-37

Source registry

EUCTR

Status

Ongoing

Phase

PHASE4

Sponsor

Department of Medicine I, University Hospital St. Josef-Hospital, Ruhr University Bochum

Start date

2008-07-08

Last update

2026-08-16

Conditions

• Non alcoholic steatohepatitis (NASH)

Summary

The primary objective of this study is to test the hypothesis that 24 weeks of treatment with exenatide will improve the histological activity of NASH (steatosis, necroinflammation, ballooning), summarized in the recently introduced NASH-Score (appendix 1) in patients with normal, impaired or diabetic glucose tolerance compared to dietary guidance alone.

Locations

• , , Germany

View on source registry